FDA approves combo eye drop for glaucoma

U.S. regulators approved a new glaucoma treatment—Combigan, an eye drop that treats the potentially blinding eye condition with two drugs that work through different mechanisms, Allergan Inc said Wednesday.

Allergan, best known for its Botox anti-wrinkle drug but is also a leading provider of eye medications and products, said its new drug would be introduced in the fourth quarter of 2007.

The company said Combigan would combine “two strong agents in one bottle”—brimonidine and timolol—to control pressure within the eye that can harm the optic nerve. 

Print Version
Tell-a-Friend

RELATED ARTICLES:

No mental effects seen with Arimidex   Guide helps doctors manage vaccine allergies   Class of Diabetes Drugs Carries Significant Cardiovascular Risks   Many Hispanics with diabetes unaware of potential eye disease, do not receive eye exams   Medication improves alcoholics’ quality of life   Eating fish may curb risk of age-related eye disease   Glaucoma vision loss leads to more health problems   Experimental drug lowers blood sugar in diabetics   Higher co-payments reduce use of antidepressants   Paralysed Israeli paints with his eyes   Synthetic molecules hold promise for new family of anti-cancer drugs   Search for an HIV Vaccine Must Go On Says Expert in Light of Recent High-profile Merck Failure